Feedback from the FDA meeting emphasized the criteria involved in developing galantamine as a neuroprotectant against nerve agent exposure. Among other aspects, FDA guidance supported the use of the “Animal Rule” as the appropriate regulatory path.
Feedback from the FDA meeting emphasized the criteria involved in developing galantamine as a neuroprotectant against nerve agent exposure. Among other aspects, FDA guidance supported the use of the “Animal Rule” as the appropriate regulatory path.